Logo

OA is associated with a reduction of the molecular weight and concentration of HA in the synovial fluid causing a worsening of its rheological properties and contributing to OA progression1

 

Hyalone® for TEMPORARY SYNOVIAL FLUID REPLACEMENT reducing pain symptoms and improving joint functionality2

Composition

Hyaluronic acid sodium salt (60mg/4mL) obtained by bacterial fermentation from a fraction of high molecular weight2

Available Presentation

Box containing 1 pre-filled syringe sealed in a blister2

Indications

Treatment of pain and improvement of joint functionality in patients affected by degenerative or mechanical arthropathy of the knee and hip joint2

Dosage & Administration

Treatment cycle:
1 injection2

Available PRESENTATION

Box containing 1 single dose.

PRODUCT PORTFOLIO

VISCOSUPPLEMENTATION

Medical Devices CE0459.
Read the instructions for use carefully.

References:
1. Migliore A et al, J Rare Dis Res Treat. 2019;
2. HYALONE® Patient Information Leaflet.;

You are about to leave fidiajointcare.com

All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.

Proceed